Ray Co

Ray Co Financing Cash Flow

The Net Financing Cash Flow of Ray Co (228670.KQ) as of Nov 18, 2026 is 9.13 B KRW. In the previous year, Net Financing Cash Flow was 21.63 B KRW — a change of -57.77% (lower).

Financing Cash Flow

9.13 BKRW

YoY

-57.77%

Last updated:

Net Financing Cash Flow of Ray Co is 2024 9.13 B KRW. Net Financing Cash Flow of Ray Co was 2023 21.63 B KRW. It decreases by -57.77% lower compared to the previous year.

The Ray Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
1.00 B KRW
Jan 1, 2018
6.04 B KRW
Jan 1, 2019
17.15 B KRW
Jan 1, 2020
5.78 B KRW
Jan 1, 2021
70.79 B KRW
Jan 1, 2022
16.69 B KRW
Jan 1, 2023
21.63 B KRW
Jan 1, 2024
9.13 B KRW
The Ray Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
9.13 BKRW-57.77%
21.63 BKRW+29.56%
16.69 BKRW-76.42%
70.79 BKRW+1,124.69%
5.78 BKRW-66.30%
17.15 BKRW+184.10%
6.04 BKRW+502.97%
1.00 BKRW-84.04%
6.27 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ray Co Stock analysis

What does Ray Co do? Ray Co., Ltd. generates revenue through the manufacturing and sale of advanced technology medical devices, focusing on digital diagnostic systems and digital therapy solutions. The company produces dental radiography equipment such as x-ray systems and cone beam computed tomography (CBCT) systems, alongside 3D scanning, dental computer aided design (CAD), and 3D printers for prosthodontics, orthodontics, and implant surgery. Domestic and overseas markets purchase these products, with the company operating through subsidiaries to distribute its offerings globally. Digital diagnostic systems like dental radiography equipment and CBCT systems are sold to healthcare providers and dental clinics, while digital therapy solutions including 3D scanning and CAD systems target dental laboratories and surgical centers. The firm's product portfolio serves both domestic and international clients, leveraging its subsidiaries for global distribution channels. Ray Co., Ltd. emphasizes advanced technology in its medical device offerings, with digital therapy solutions such as 3D printers and CAD systems being key revenue drivers. The company's focus on dental-specific applications ensures targeted sales to specialized healthcare segments, including prosthodontics, orthodontics, and implant surgery practices. Ray Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ray Co stock

Net Financing Cash Flow of Ray Co is 9.13 B KRW in 2024.

Net Financing Cash Flow of Ray Co changed from 21.63 B KRW to 9.13 B KRW, representing a -57.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Ray Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Ray Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ray Co

All Key Metrics — Ray Co